L020 Stock Chart & Stats
€0.03
<€0.01(3.57%)
At close: 4:00 PM EDT
€0.03
<€0.01(3.57%)
Day’s Range― - ―
52-Week Range€0.03 - €0.07
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.08M
Enterprise Value>-€0.01
Total Cash (Recent Filing)€12.41M
Total Debt (Recent Filing)€211.52K
Price to Earnings (P/E)0.8
Beta-1.08
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding162,254,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.70
Price to Sales (P/S)30.75
P/FCF Ratio-12.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage reduces fixed financial obligations and gives the company greater flexibility to manage operating volatility. Compared with debt-to-equity ratios of roughly 3.0–3.8 in 2022–2024, the current capital structure provides a stronger base for funding operations and absorbing setbacks.
Substantial Equity CushionThe sizable equity base relative to assets provides an important financial cushion while the company works through weak operating results. This capital support can reduce dependence on borrowing and preserve strategic flexibility, although it does not by itself resolve the need to restore sustainable profitability.
Prior Positive Cash GenerationPositive operating and free cash flow in earlier periods shows that the business has previously converted activity into cash, rather than relying exclusively on external funding. That history offers a basis for potential recovery if revenue and operating performance improve, despite the recent reversal into cash burn.
Bears Say
Small And Declining Revenue BaseA very small and shrinking revenue base limits operating scale, reduces the ability to absorb fixed costs, and makes results more vulnerable to individual contract or activity changes. Until revenue growth returns, the company has limited evidence of durable market traction or a stable platform for expansion.
Weak Core ProfitabilityDeeply negative EBIT and EBITDA margins indicate that the underlying operation is not currently covering its costs, while the modest gross margin leaves little room to fund overhead or reinvestment. This weak cost structure makes sustained earnings improvement dependent on a meaningful operational turnaround.
Negative And Volatile Cash FlowRecent cash burn weakens financial resilience and can create funding pressure if it persists, even with low leverage. The sharp contrast with positive cash flow in 2022–2024, alongside volatile earnings quality, makes it difficult to rely on current operations to finance growth or maintain stability.
Britannia Life Sciences Inc News
L020 FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was €0.03 and its highest was €0.07 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is €7.08M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Nov 26, 2026 which is in 72 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Jul 29, 2026. The company reported €0.004 earnings per share for the quarter.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of €0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in DE:L020
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics, nutraceutical, and consumer packaged goods (CPG) sectors, operating extensively throughout the United Kingdom and various international markets.